International Evidence-Based Kyoto Guidelines for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas

Front

1 of 3 · Front

📘 GuidelineCh 3 · Hepatobiliary, Pancreatic & Splenic Surgery

International Evidence-Based Kyoto Guidelines for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas

In one breath

The evidence-based Kyoto guidelines for pancreatic IPMN: revised high-risk stigmata and worrisome features, a revised management algorithm, and — after 5 years of stability in a small unchanged branch-duct IPMN — either stopping surveillance or continuing it, by shared decision.

Edition2024 (Kyoto)

Issued byInternational Association of Pancreatology (IAP) Kyoto working group

Place of issueInternational

PublishedPancreatology · 2024;24(2):255–270

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers IPMN, including branch-duct, main-duct, and mixed-type disease; diagnosis, high-risk stigmata/worrisome features, surveillance, cyst-fluid markers, surgery, and post-resection surveillance.

Applies to: Adults with suspected or diagnosed pancreatic IPMN, including patients after resection of non-invasive IPMN.

§2 · Key recommendations

Revises high-risk stigmata and worrisome features.
integrates EUS/contrast-enhanced EUS findings and EUS-FNA cytology when performed.
provides a revised management algorithm.
discusses cyst-fluid molecular markers.
after 5 years of stability in a small unchanged branch-duct IPMN, offers either stopping surveillance or continuing surveillance for possible concomitant PDAC, after shared decision-making.
Post-resection follow-up is risk-stratified.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

The source record does not reproduce this guideline's evidence framework or grading: 'Evidence/grade not fully reproduced in report block; consult original source' Per-recommendation certainty and strength: Not yet established — pending verification.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Ohtsuka T, et al. International Evidence-Based Kyoto Guidelines for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreatology. 2024;24(2):255–270. doi:10.1016/j.pan.2023.12.009.

Publisher — the record's original_url, carried verbatim ↗DOI — 10.1016/j.pan.2023.12.009 ↗

Link check 2026-11-11: the publisher (ScienceDirect) URL fetched live — HTTP 200; the DOI resolved at Crossref with matching title, journal, volume and pages.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #54, Domain 05) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): IPMN surveillance — Kyoto 2024 vs more conservative lifelong-surveillance approaches. Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div03-kyoto-ipmn-2024GS.code · Guidelines